Transvaginal mesh Uphold TM Vaginal Support System
DeviceOther names: Transvaginal mesh Uphold TM Vaginal Support System.
NCT Number: NCT03077490
Comparison of single versus multicenter outcomes for pelvic organ prolapse repair using a mesh-capturing device (The Uphold™ Vaginal Support System for apical and vaginal wall prolapse - Boston Scientific). 1-2 years follow up study comprison of 112 vs 207 patients.
Looking for future studies?
Notify Me18 year–90 year
Female
Observational
112 women operated by two surgeons at one center (2 years follow up) are to be compared to 207 women operated by twenty six surgeons at twenty four centers (1 year follow-up).
Screening at baseline for apical (uterine or vaginal vault) prolapse stage II with or without concomitant anterior or vaginal wall prolapse ≥ stage 2 according to the pelvic organ prolapse quantification (POP-Q) system.
Surgical data including operation data, complications and hospital stay are to be compared.
Anatomical outcome measurements by POP-Q evaluations. Subjective symptoms are to be evaluated by prolapse specific symptom questionnaires (PFIQ-7, UDI-6 and PFIQ) whereas sexual function to be estimated by PISQ-12.
Only the study team can determine whether someone qualifies for participation.
Inclusion
Exclusion criteria
Other names: Transvaginal mesh Uphold TM Vaginal Support System.
Time frame: From operation start to hospital discharge, assessed for an estimated total of days (1-7 days).
Serious surgical complications are categorized as any surgical event which is potentially life-threatening related to the surgical procedure including: internal organ perforation (or other injury), bleeding in excess of 1000 mL.
Time frame: From hospital discharge and up to 2 years at single center and 1 year at multicenter
Adverse events during follow-up which requires re-hospitalisation or surgical re-intervention.
Time frame: 2 years vs 1 year
Anatomical outcome is a composite definition including point C positioned above a point corresponding to half of the total vaginal length. The overall POP-Q outcomes will be analyzed to determine efficacy of the procedure related to correction of anterior prolapse ≥stage II or other defects present at the time of surgery. Days in hospital are counted from the day of surgery i.e. the day of operation is day 1 and the day of returning home is the last day of hospital stay.
Time frame: 2 years vs 1 year
Subjective outcome is the patients' response 'no' to question 2 of the PFDI (pelvic heaviness). The composite outcome is a strictly binary categorization where any residual sense of pelvic heaviness/vaginal bulging results in the classification of the patient as a failure. It also includes the components of the main secondary outcome considered individually, any adverse events in the aftermath of surgery, as well as, patient-reported urogenital distress (UDI), quality of life (PFIQ) and sexual function (PISQ-12) as measured by the self-reported questionnaires. For secondary analyses, the ordinal grading of responses to the PFDI-20, PFIQ-7 and PISQ-12 will be used to determine rates of improvement and progression over time.
Time frame: 5, 7, 10 years
Mesh measurements: Total mesh midsagittal length, length above and below the bladder neck (BN) level. Distance between mesh lower edge and pubis symphysis (PS) lower edge and PS level.
Bladder neck: Distance between BN and PS levels. Distance between BN and PS lower edge.
Urethra: Total urethra length. Distance between mid-urethra and PS lower edge and PS level.
Using identical examination protocol, independent examination at rest and physical strain is to be done by senior gynecologist at an ultrasound referral unit and gynecologist. Estimation of intra class coefficient (ICC) in-between examiners in order to determine method reproducibility.
To statistically compare between the collected ultrasound data and clinical outcomes. Clinical outcomes include anatomical, subjective and sexual function outcome.
Time frame: Changes from baseline, 2, 5 and 10 years after surgery
VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of pain.
Time frame: Changes from baseline, 2, 5 and 10 years after surgery
VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of severity of urinary incontinence. VAS scale for urinary incontinence: 0 indicate no urinary incontinence whereas 10 indicates maximal or severe urinary incontinence.
Time frame: assessment at 2, 5 and 10 years after surgery
VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of satisfaction after mesh surgery. VAS scale for patient satisfaction: 0 indicates no satisfaction whereas 10 indicates maximal satisfaction.
Time frame: assessment at 2, 5 and 10 years after surgery
VAS scale is a numeric rating scale and ranges from 0-10 (each digit is 1cm) where 0 indicates no and 10 indicates maximum, digits between 0-10 indicate degree of satisfaction. VAS scale for patient recommendation to other patients to undergo same surgery if they suffer apical prolapse: 0 indicates no recommendation whereas 10 indicates maximal recommendation.
Karolinska Institutet
Other
Acronym: KIDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07194343
Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms
Barcelona, Spain
View Trial DetailsNCT05463081
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Tver', Tver Oblast, Russia
View Trial DetailsNCT03947164
Prolapse Genital
Rennes, Brittany Region, France
View Trial DetailsNCT05571072
Neurologic Manifestations, Opioid Use
Cleveland, Ohio, United States
View Trial Details